LQLiquidia LQDA NASDAQ · Healthcare · United States
$56.40 -0.58% -$0.33
- Market cap
- $5.08B
- Enterprise value
- $4.85B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 8.2x
- P/FCF
- 25.3x
- EV/EBITDA
- -
- ROIC
- -55.7%
- Gross margin
- 92.7%
- Net margin
- -15.1%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.54
- Free float
- 73.0%
About the company
Liquidia Corporation is a small U.S. biotechnology company focused on the treatment of pulmonary arterial hypertension (PAH). Its main product, Yutrepia, is an innovative inhaled formulation of treprostinil based on its proprietary PRINT technology, which enables precise particle engineering and more efficient delivery of the drug into the lungs. Liquidia aims to provide patients with a more convenient and cost-effective alternative to established therapies such as Tyvaso from United Therapeutics, positioning itself as a potential disruptor in the market. Although the company has significantly smaller financial resources and is not yet profitable, the success of Yutrepia and potential portfolio expansion could secure rapid growth and capture part of the multi-billion-dollar PAH treatment segment.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Roger A. Jeffs
Employees
216
Headquarters
Morrisville
Valuation
Is today's price reasonable?
- What speaks for it: The share price is below the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Revenue grew by 115% a year over the last 3 years.
- What to watch: It missed profit estimates 4 times in the last 8 quarters.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 USD of revenue, 32 USD is left as free cash.
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $396.1M against $168.8M.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number